Tempus ECG-Low EF vs Tempus ECG-AF
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary goal is to identify patients aged 40 or older who may currently be at risk for heart failure due to a low left ventricular ejection fraction (LVEF ≤40%). This tool is ideal for aiding clinicians in the early detection and subsequent evaluation of individuals showing signs associated with reduced cardiac pumping efficiency.
View Tempus ECG-Low EF →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation or flutter within the next 12 months. This tool is best suited for supporting earlier identification and follow-up strategies for older adults without pre-existing AF, enabling timely interventions to manage future cardiac rhythm disorders.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth Tempus ECG-Low EF and Tempus ECG-AF are designed as software solutions that integrate into existing healthcare facility workflows and systems. Neither tool has a dedicated user interface, with input and output handled through standard communication protocols with other medical systems. This indicates a similar approach to usability, focused on seamless backend integration rather than direct user interaction.
Clinical Value
Tempus ECG-Low EFTempus ECG-Low EF (Tool A) detects signs associated with low LVEF (u226440%) with reported sensitivity of 85.8% and specificity of 83.0% on an independent validation cohort, aiding in the identification of patients at risk of heart failure. While Tempus ECG-AF (Tool B) predicts the risk of developing atrial fibrillation within 12 months, its reported sensitivity is lower at 31%, despite a high specificity of 92%. Tool A's higher sensitivity and specificity for detecting an existing, critical condition suggest a more robust immediate clinical impact.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly states that CMS reimbursement is available, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90 effective January 1, 2025. This transparency regarding reimbursement provides a clear financial value proposition and facilitates adoption for healthcare providers. Tempus ECG-Low EF (Tool A) only indicates 'contact vendor' for pricing, offering no immediate insight into its economic value or reimbursement pathways.
Enterprise Readiness
TieBoth Tempus ECG-Low EF and Tempus ECG-AF are FDA-cleared, HIPAA compliant, and have Business Associate Agreements (BAAs) in place. Both are deployed as software solutions integrated into healthcare facility systems and workflows. These foundational elements demonstrate equal readiness for enterprise-level deployment and adherence to critical regulatory and operational standards.
Innovation
Tempus ECG-AFWhile both tools leverage AI for ECG analysis, Tempus ECG-AF (Tool B) stands out for its innovative application in predicting the *future* onset of atrial fibrillation within 12 months. This predictive capability, trained on a larger dataset of over 1.5 million ECGs, represents a more advanced step in proactive risk identification and preventative care compared to detecting signs of an *existing* condition, even if undiagnosed.
Support & Docs
TieThe provided structured facts and web search results do not offer specific differentiating information regarding the support or documentation for either Tempus ECG-Low EF or Tempus ECG-AF. As both products are from the same company, Tempus AI, it is reasonable to infer that they would share a common support infrastructure and access to general company documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | Tempus ECG-AF |
|---|---|---|
| Product Name | Tempus ECG-Low EF | Tempus ECG-AF |
| Description | Tempus ECG-Low EF is an FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Target Condition | Low Left Ventricular Ejection Fraction (LVEF u226440%) | Atrial Fibrillation/Flutter (AF) |
| Target Patient Population | Patients 40 years or older at risk of heart failure | Patients aged 65 or older at increased risk of developing AF within the next 12 months, without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery |
| Output/Detection | Binary output (Low LVEF Detected / Not Detected) | Identifies patients at increased risk of developing Atrial Fibrillation (AF) within 12 months |
| Training Data Size (ECGs) | Over 930,000 ECGs | Over 1.5 million ECGs |
| CMS Reimbursement | Not specified | Available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025) |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or Tempus ECG-AF
Backers
Who funded each tool's parent company.